Atecegatran (TFA)

• Description :

  Atecegatran TFA (AR-H067637 TFA) is an anticoagulant with selective direct thrombin inhibitory activity. Atecegatran TFA is commonly used to inhibit cardiovascular diseases. The biotransformation product of Atecegatran TFA, AR-H067637, is its active form and participates in the anticoagulation process[1].

• CAS Number :

  [433937-75-8]

• Product Name Alternative :

  AR-H067637 (TFA)

• UNSPSC :

  12352005

• Target :

  Thrombin

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/atecegatran-tfa.html

• Smiles :

  OC(C(F)(F)F)=O.O[C@H](C1=CC(OC(F)F)=CC(Cl)=C1)C(N2[C@@H](CC2)C(NCC3=CC=C(C=C3)C(N)=N)=O)=O

• Molecular Formula :

  C23H22ClF5N4O6

• Molecular Weight :

  580.89

• References & Citations :

  [1]Deinum J, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009 Jun;101 (6) :1051-9.|[2]Deinum J, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009 Jun;101 (6) :1051-9.|[3]Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported